<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11573">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956278</url>
  </required_header>
  <id_info>
    <org_study_id>14-14550</org_study_id>
    <secondary_id>R01DK103729</secondary_id>
    <nct_id>NCT02956278</nct_id>
  </id_info>
  <brief_title>The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Open Medicine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      Subjects will undergo a placebo and allopurinol phase to better understand the effects of
      the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and
      pharmacodynamics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Allopurinol/Oxypurinol Renal Clearance</measure>
    <time_frame>as determined by blood/urine levels taken over the course of one week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Uric Acid Levels</measure>
    <time_frame>as determined by blood/urine levels taken over the course of one week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allopurinol/Oxypurinol steady state concentrations</measure>
    <time_frame>as determined by blood/urine levels taken over the course of one week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Chronic Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take a placebo and provide blood/urine samples for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take allopurinol for 6 days. On day 1 and 6, subjects will provide blood and urine samples for 24 hours. Subjects will provide additional blood samples on days 7 and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>lactose placebo pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  self-identified as Asian/European ancestry

          -  generally healthy with approved lab values for CBC,HFP,RFP, and uric acid

          -  Subjects with the ABCG2 genotype, homozygous, heterozygous or homozygous for the
             major allele of rs2231142 will be recruited

        Exclusion Criteria:

          -  vascular disease

          -  renal impairment

          -  medications/supplements that affect uric acid levels

          -  pregnant or lactating women

          -  prior history of allergic reaction to allopurinol or testing positive for HLA-B*5801
             allele

          -  risk of urinary or gastric retention or narrow-angle glaucoma

          -  impaired hepatic function

          -  evidence of anemia

          -  evidence or diagnosis of congestive heart failure

          -  smokers

          -  subjects with a mutation other than rs2231142 in the ABCG2 genotype

          -  subjects taking hormonal contraceptives or other hormonal medications

          -  evidence of recreational drug use as determined by questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Giacomini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deanna Brackman</last_name>
    <phone>6144397096</phone>
    <email>deanna.brackman@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Open Medicine Institute</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catt Phan</last_name>
      <phone>650-691-8633</phone>
    </contact>
    <investigator>
      <last_name>Andy Kogelnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 2, 2016</lastchanged_date>
  <firstreceived_date>November 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allopurinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
